Media Center

Perspectives on Universal Healthcare Coverage

The innovative biopharmaceutical industry believes that a structured, collaborative effort to achieve universal health coverage can meet the shared goals of global health stakeholders of expanding patient access to quality medicines through innovative solutions and long-term sustainability of the health sector.

Novartis partners with Malaria No More to provide treatment in Zambia

Novartis announced on Monday that it will partner with Malaria No More and the Power of One campaign to provide two million pediatric antimalarial treatments in Zambia.

“Although the incidence of malaria has decreased, the disease still kills a child every minute in Africa,” Novartis CEO Joseph Jimenez said. “Our commitment to Power of One reflects our company’s long-term efforts to fight malaria and Novartis remains dedicated to controlling and ultimately eliminating this deadly disease.”

Uniting to Combat Neglected Tropical Diseases: A Conversation on Progress

On April 2, the Uniting to Combat Neglected Tropical Diseases: A Conversation on Progress webcast and live Q&A will be broadcast from Institut Pasteur in Paris from 18:00 - 19:30 Central European Summer Time/12:00 - 13:30 Eastern Daylight Time. Panelists will address progress and challenges in the effort to control and eliminate 10 NTDs by 2020, with an overarching theme of how the unique alliance of pharmaceutical companies, development agencies, endemic countries, research organizations and private foundations has driven progress forward since the launch of the London Declaration on Neglected Tropical Diseases in 2012.

WHO South-East Asia Region certified polio-free

WHO South-East Asia Region, home to a quarter of the world’s population, was certified polio-free today by an independent commission under the WHO certification process. This is the fourth of six WHO Regions to be certified, marking an important step towards global polio eradication. With this step, 80% of the world’s population now lives in certified polio-free regions.

Pharmaceutical R&D Projects to Develop New Cures for Patients with Neglected Conditions

The research-based pharmaceutical industry is actively involved in the fight against diseases affecting vulnerable populations. With 162 compounds in development, R&D programs and pipelines show industry’s commitment to these pressing health challenges. Most of these R&D projects are carried out through innovative collaborations with non-industry partners.

Eliminating or controlling neglected diseases is achievable. Success relies on multi-stakeholder approaches, which not only drive further R&D but also integrate environmental improvements, boosting capacity-building efforts, effective health policies, better screening, and availability of high quality, safe and effective medicines.

Patients’ Needs, Medicines Innovation and the Global Public’s Interests

New pharmaceutical and other treatments combined with the world-wide development of universally accessible health care systems could effectively eliminate infectious and noncommunicable disease-related deaths in people aged under 70 by the middle of this century, according to a new report from the London School of Economics and Political Science and the UCL School of Pharmacy, published today. Patients’ Needs, Medicines Innovation and the Global Public’s Interests shows that global life expectancy at birth increased by 30 years over the course of the last century, from 40 years to 70 years. Half of this progress has been due to health care technologies such as innovative vaccines and medicines.

Rethinking Pharmaceutical Business Models

The world’s health needs are changing dramatically. Demographic trends, shifting patterns of disease, and strained public funding are placing new burdens on health-care systems. For developed and developing countries alike, the new demands cannot be met if health care continues to operate in the same way. What is required are new business models that spread risks, take a broader view of health, and address the needs of the world’s poorest people.

Action on Neglected Tropical Diseases in India

India has the highest burden of NTDs in the world, which disproportionally affect those from the poorest and most marginalised communities and locks people into a cycle of poverty and disease. Stakeholders agree that there is a joint moral obligation to prevent, control, eliminate and ultimately eradicate NTDs in India (and globally). Strong multi- stakeholder partnerships will be the critical element to fully understanding the burden of disease, increasing R&D, integrating approaches and building political and economic will for NTD interventions.
Read the full report.

India to Strengthen R&D of New Diagnostics, Vaccines & Treatments for Neglected Tropical Diseases

Leading the global fight against Neglected Tropical Diseases (NTDs), India is moving to strengthen efforts to eradicate the neglected tropical diseases such as dengue, visceral leishmaniasis (Kala azar), soil-transmitted Helminths, among others that affect millions of Indians every year especially children. There is urgent need to accelerate research and development for new tools, medicines and indigenous tests that target pathogen strains that are locally prevalent and adopt and accelerate strategies to reach the poorest and most marginalized populations who are most afflicted by NTDs.

Addressing neglected tropical diseases: research, development and access to treatments

According to the WHO, Neglected Tropical Diseases (NTDs) affect over 1 billion people worldwide, and are devastating to patients in the developing world. These diseases kill or disable millions of people every year. These diseases were highlighted in a recent PhRMA Conversation in which PhRMA President and CEO John J. Castellani asked a variety of experts for their opinion on "What is being done to get treatments to these patients and to speed development of new treatments?" The 2013 G-FINDER report was also recently released, addressing global funding of innovation for neglected diseases.